Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Fig. 2

Kaplan-Meier curves for the DFS outcomes among patients without trastuzumab (group 1). Patients in group 1 (255) were divided into two subgroups on average, low and high pre-NLR subgroup 1, according to the values of pre-NLR. Patients in low and high pre-NLR subgroup 1 showed no significant difference in DFS outcome. DFS, disease-free survival; pre-NLR, pretreatment neutrophil/lymphocyte ratio

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us